The Budget Line That Ate the Site
You are negotiating a budget with a community site for a Phase II dermatology trial. The sponsor's per-subject budget is $9,800. The site's proposed budget totals $14,200 per subject, driven by a $3,400 "administrative fee" and a $1,100 per-visit charge for a visit the protocol describes as a phone call. The site also wants a 30% overhead on all pass-through costs (central lab, imaging) and payment on a monthly invoice basis regardless of enrollment. The site has enrolled well in prior studies but has a history of slow invoice reconciliation. Your total study budget is fixed; enrolling this site is important because it serves a patient population your other sites don't reach. The contract must be executed in three weeks to meet the startup timeline.
1. Where do you push back, where do you concede, and how do you structure the deal?
Read the worked answer
Push back hard:
- The $1,100 "phone call" visit. Price it at the actual effort (typically $150-300). Anchor to the protocol, not the site's wish list. If the site insists, ask them to show the effort - a phone visit does not carry the same cost as an on-site visit with procedures.
- 30% overhead on pass-throughs. Pass-through costs (central lab, imaging) are not the site's costs to mark up. Cap overhead at a defensible rate (often 15-25% on site-performed procedures, not on third-party invoices) and require the site to pass through actual invoices.
- Monthly invoicing regardless of enrollment creates a cash-flow mismatch and removes the site's incentive to enroll. Tie payment to milestones: startup, per-subject screening, per-subject randomization, per-visit completion, closeout.
Concede selectively:
- The $3,400 administrative fee may be a real cost (regulatory, pharmacy, IRB) - ask for a breakdown. If it reflects genuine startup burden, move part of it into a one-time startup fee rather than per-subject, which reduces per-subject cost as enrollment grows.
- Total per-subject can land near the sponsor's $9,800 if you restructure rather than cut line by line.
Structure: Fixed startup fee + per-subject milestone payments + pass-through at actuals with capped overhead. Hold back a modest closeout payment to ensure reconciliation.
2. The site won't move below $12,000, and you have three weeks. What is your decision framework?
Read the worked answer
First, quantify what the site is actually worth.
- If this site brings a patient population no other site reaches, the marginal value of access may justify a premium - but a premium must be justified and documented, not conceded under time pressure.
- Compare $12,000 against your blended per-subject cost across all sites. If the study average is $10,500, this site is 14% above average - potentially acceptable if the enrollment value is real. If it's 40% above, the budget breaks.
Second, separate the price from the risk:
- The site's slow reconciliation history is a financial risk, not a price issue. Mitigate it with milestone payments, a reconciliation requirement before final payment, and a clear invoice-dispute process in the contract.
- A fixed total budget means a premium here must come from somewhere - identify which line absorbs it, or escalate to the sponsor for a budget amendment. Do not silently absorb it and discover the overrun at month 6.
Third, the three-week deadline:
- A contract executed in three weeks to hit startup is a real constraint, but signing a bad contract faster is not a solution. If the site won't move, escalate to your contracts lead and the sponsor now - a two-week extension on startup is cheaper than a three-year budget dispute.
Decision: If the site's patient access is genuinely unique and the premium is defensible against the blended cost, sign at a restructured $12,000 with milestone payments and reconciliation controls, documented with a written rationale. If not, walk and reallocate the enrollment target. "Important" is not the same as "at any price."